Athens Research/Cambio - Excellence in Molecular Biology/300U/PM-1390-01

价格
面议
货号:PM-1390-01
浏览量:72
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Enzymes for Molecular Biology

Enzymes for Molecular Biology: Enzymes for Molecular Biology

  • Catalogue
  • Description
  • Protocols
  • References

Terminal Deoxynucleotidyl Transferase

Terminal Deoxynucleotidyl Transferase catalyses the transfer of deoxynucleoside monophosphate from deoxynucleoside triphosphate to 3"-OH termini of DNA molecules or oligonucleotide initiators

Cambio

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
PM-1390-01Terminal Deoxynucleotidyl Transferase300U£105.00QuantityAdd to Order
PM-1390-02Terminal Deoxynucleotidyl Transferase1,500U£240.00QuantityAdd to Order

Terminal Deoxynucleotidyl Transferase

Terminal Deoxynucleotidyl Transferase catalyses the transfer of deoxynucleoside monophosphate from deoxynucleoside triphosphate to 3"-OH termini of DNA molecules or oligonucleotide initiators

Cambio

Applications

  • Preferred substrates are single-stranded DNA, double-stranded DNA with 3’-hydroxyl termini and oligodeoxynucleotide primers (1)
  • Used for specific labelling of 3"-termini with ribonucleotides (2)
  • Labels 3"-ends of DNA fragments with an [α-32P] 3"-deoxynucleoside (3)
  • Adds homopolymer tails of deoxyribonucleotides to vectors or cDNAs (4,5)

Reagents Supplied

5X Tdt C-Tailing Reaction Buffer

Unit Definition

One unit is the amount of enzyme required to transfer 1 nmol of dAMP from dATP to the 3" OH terminus of the oligonucleotide initiator d(A)15 for 1 hour at 37ºC

Heat Inactivation

15 minutes at75ºC

Concentration

10-15 units/µl

Storage Buffer

50 mM potassium phosphate (pH 7.4)1 mM β-mercaptoethanol50% (w/v) glycerol

Assay Conditions

40 mM K Cacodylate (pH 7.2)8 mM MgCl20.33 mM ZnSO410 µM oligonucleotide d(A)5010 µlbovine serum albumin buffer1 mM (α-32P) dATP Reaction volume of 60 µl

Note: All reactions should be run in polypropylene tubes

Storage Conditions

Store at -20°C

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Terminal Deoxynucleotidyl Transferase

Terminal Deoxynucleotidyl Transferase catalyses the transfer of deoxynucleoside monophosphate from deoxynucleoside triphosphate to 3"-OH termini of DNA molecules or oligonucleotide initiators

Cambio

Download here

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Terminal Deoxynucleotidyl Transferase

Terminal Deoxynucleotidyl Transferase catalyses the transfer of deoxynucleoside monophosphate from deoxynucleoside triphosphate to 3"-OH termini of DNA molecules or oligonucleotide initiators

Cambio

(1) Chang, L.M. and Bollum, F.J. (1971) J. Biol. Chem. 246, 909-916(2) Roychoudury, R. and Kossel, H. (1971) Eur. J. Biochem. 22. 310-320(3) Tu, C.P.D. and Cohen, S.N. (1980) Gene 10, 177-183(4) Roychoudhury, R., Jay, E. and Wu, R. (1976) Nucleic Acids Res. 3, 863-877(5) Deng, G. and Wu, R. (1983) Methods Enzymol. 100, 96-116

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.